Integral Derivatives’s Medicines Co MDCO Stock Holding History

Integral Derivatives’s Portfolio MDCO Stock Details MDCO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-6,000	Closed	-$293K	–	1355
2017 Q1	$293K	Sell	6,000 -22,300	-79%	-$1.02M	0.01%	914
2016 Q4	$961K	Buy	+28,300	New	+$1M	0.02%	525
2016 Q1	–	Sell	-6,600	Closed	-$246K	–	1198
2015 Q4	$246K	Buy	+6,600	New	+$249K	0.01%	872

Other funds holding MDCO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Integral Derivatives's MDCO Position: Q1 2017 in Review

Integral Derivatives sold out of Medicines Co (MDCO) in Q1 2017, closing a stake of 21,025 shares — an estimated $959K sold.

Integral Derivatives first reported a position in MDCO in Q4 2016 and held it in 1 quarter. The position peaked at $714K in Q4 2016. 220 funds tracked by Wall St. Rank hold MDCO as of Q1 2017.

Integral Derivatives reported no remaining Medicines Co position as of Q1 2017 after selling out during the quarter.
Integral Derivatives sold 21,025 Medicines Co shares in Q1 2017, an estimated $959K.
Integral Derivatives first reported a position in Medicines Co in Q4 2016 and held it in 1 quarter.
Integral Derivatives's Medicines Co position peaked at $714K in Q4 2016.
220 funds tracked by Wall St. Rank held Medicines Co as of Q1 2017.

Based on Integral Derivatives's 13F filing for Q1 2017, filed 15 May 2017.